Phase 1 Study Results of GS-5718, an Oral IRAK4-Inhibitor: Pharmacodynamics of Single and Multiple Doses of GS-5718 in Healthy Subjects

被引：0
|
作者：
Roedder, Silke [1 ]
Wendt, Emily [2 ]
Burris, Chad [2 ]
Nazareon, Jonathan [2 ]
Park, Grace [3 ]
Pangilinan, Phil [2 ]
Huang, Gianna [2 ]
Mathur, Anubhav [2 ]
Taylor, James [2 ]
Billin, Andrew [2 ]
Matzkies, Franziska [4 ]
机构：
[1] Gilead Sci, Menlo Pk, CA USA
[2] Gilead Sci, Foster City, CA USA
[3] Gilead Sci, Seattle, WA USA
[4] Gilead Sci Inc, Foster City, CA USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2021年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0185
引用
收藏
页码：371 / 372
页数：2
相关论文
共 50 条
  • [21] A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of V-7404 in Healthy Adult Volunteers
    Kankam, Martin K.
    Burns, Jennifer M.
    Collett, Marc S.
    Corrado, Michael L.
    Hincks, Jeffrey R.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (10)
  • [22] Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult Subjects
    Rubino, Christopher M.
    Bhavnani, Sujata M.
    Loutit, Jeffery S.
    Morgan, Elizabeth E.
    White, Dan
    Dudley, Michael N.
    Griffith, David C.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (04)
  • [23] Safety, tolerability, and pharmacokinetics of single and multiple ascending Oral doses of DA-8010 in healthy subjects: First-in-human phase I study
    Lee, Dae Young
    Lee, Min Jung
    Ryu, Chaelim
    Lee, Heewon
    Brooks, Ashley
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2023, 11 (01):
  • [24] Safety, Pharmacokinetics, and Pharmacodynamics of the New Aldose Reductase Inhibitor Govorestat (AT-007) After a Single and Multiple Doses in Participants in a Phase 1/2 Study
    Perfetti, Riccardo
    Bailey, Evan
    Wang, Stella
    Mills, Richard
    Mohanlal, Ramon
    Shendelman, Shoshana
    JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 64 (11): : 1397 - 1406
  • [25] Adverse Events in Healthy Subjects Exposed to Single and Multiple Doses of LY2140023 Monohydrate Pooled Results From 10 Phase 1 Studies
    Ayan-Oshodi, Mosun
    Wondmagegnehu, Eshetu T.
    Lowe, Stephen L.
    Kryzhanovskaya, Ludmila
    Walker, Daniel J.
    Kinon, Bruce J.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2012, 32 (03) : 408 - 411
  • [26] Pharmacokinetics, Pharmacodynamics, and Safety of Dulaglutide After Single or Multiple Doses in Chinese Healthy Subjects and Patients with T2DM: A Randomized, Placebo-Controlled, Phase I Study
    Junyu Xu
    Yifei Zhang
    Yiming Li
    Xia Zhao
    Weiwei Zhou
    Corina Loghin
    Lai San Tham
    Xuewei Cui
    Yimin Cui
    Weiqing Wang
    Advances in Therapy, 2022, 39 : 488 - 503
  • [27] Pharmacokinetics, Pharmacodynamics, and Safety of Dulaglutide After Single or Multiple Doses in Chinese Healthy Subjects and Patients with T2DM: A Randomized, Placebo-Controlled, Phase I Study
    Xu, Junyu
    Zhang, Yifei
    Li, Yiming
    Zhao, Xia
    Zhou, Weiwei
    Loghin, Corina
    San Tham, Lai
    Cui, Xuewei
    Cui, Yimin
    Wang, Weiqing
    ADVANCES IN THERAPY, 2022, 39 (01) : 488 - 503
  • [28] A Phase 1 Study To Evaluate Safety and Pharmacokinetics following Administration of Single and Multiple Doses of the Antistaphylococcal Lysin LSVT-1701 in Healthy Adult Subjects
    Wire, Mary Beth
    Jun, Soo Youn
    Jang, In-Jin
    Lee, Seung-Hwan
    Hwang, Jun Gi
    Huang, David B.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (03)
  • [29] Safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of aficamten in healthy Chinese participants: a randomized, double-blind, placebo-controlled, phase 1 study
    Zhao, Xue
    Liu, Hongzhong
    Tian, Wei
    Fang, Ligang
    Yu, Mengyang
    Wu, Xiaofei
    Liu, Aijing
    Wan, Ruijie
    Li, Li
    Luo, Jinghui
    Li, Yuqiong
    Liu, Bo
    He, Yu
    Chen, Xiaowen
    Li, Yuan
    Xu, Donghong
    Wang, Hongyun
    Han, Xiaohong
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [30] PHASE 1 TRIALS OF NOVEL ORAL ENZYME THERAPY (ALLN-346) FOR HYPERURICEMIA & GOUT: SAFETY, PHARMACODYNAMICS, AND LACK OF SYSTEMIC ABSORPTION OF SINGLE AND MULTIPLE ASCENDING DOSES IN HEALTHY VOLUNTEERS
    Clark, D.
    Grujic, D.
    Tosone, C.
    Dahl, N.
    Terkeltaub, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 906 - 907
12345